ReviewCurrent neurology and neuroscience reports2025
Headache After Stroke: An Update for the Clinician.
Review in Current neurology and neuroscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewHeadache in the context of stroke is common and represents significant morbidity in the acute and outpatient settings. This article reviews recent research on the incidence, pathophysiology and management of headache secondary to ischemic and hemorrhagic stroke. RECENT
findingsMultiple studies have attempted to characterize the incidence and risk factors of post-stroke headache. Some studies regarding proposed pathophysiology exist but no clear consensus has been reached. Management strategies are limited and are typically guided by harm reduction rather than efficacy. There are some studies indicating that procedural based therapies can be both safe and effective with multiple ongoing trials focusing on ganglion blocks. The use of calcitonin-gene related peptide based therapies are limited in this setting with no robust evidence to its safety or efficacy. Headache following ischemic stroke and hemorrhagic stroke is prevalent and likely impedes recovery and quality of life. Management options are limited, though studies show promising initial results and trials are ongoing.
Indexed as
Identifiers
41364395What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.